NTLA vs BEAM
NTLA and BEAM side by side — valuation & fundamentals (public data).
Key statistics
| Metric | NTLAINTELLIA THERAPEUTICS, INC. | BEAMBeam Therapeutics Inc. |
|---|---|---|
| Market cap | $1.66B | $2.73B |
| P/B | — | 2.87 |
| P/S | 24.6x | 19.5x |
| Revenue | — | $146.64M(TTM) |
| Revenue growth (YoY) | 16.9% | 120.0% |
| Net income | — | -$108.35M(TTM) |
| Earnings growth (YoY) | 20.5% | 78.8% |
| EPS, diluted | — | $-0.88(TTM) |
| EBIT margin | -651.7% | -274.6% |
| ROE | -56.7% | -8.4% |
| ROIC | — | -45.7% |
| 1y total return | -9.3% | +8.7% |
Figures from SEC filings · for reference only · not investment advice
Crecimiento de $10,000: NTLA frente a BEAM
| Métrica | NTLA | BEAM |
|---|---|---|
| Valor final | $8.4K | $14.0K |
| Retorno total | -16.1% | +40.4% |
| CAGR | -2.6% | +5.2% |
| Volatilidad | 82.9% | 79.5% |
| Sharpe | 0.33 | 0.40 |
| Sortino | 0.50 | 0.62 |
| Caída máxima | -96.5% | -89.1% |
Basado en 1695 días de negociación comunes, 2020-02-06 → 2026-11-03 · tasa libre de riesgo 4.21% (bono corto del Tesoro actual, mantenido constante)
A head-to-head total-return backtest over real split- and dividend-adjusted prices: how a one-time $10,000 investment in each stock, held to today, would have grown over their common window — including reinvested dividends. A disclosed historical statistic — NOT a prediction, a guarantee, or investment advice. Past performance does not predict future results.
Related comparisons
Delayed data · Public sources · For reference only · Not investment advice (this page declares no winner)